Provided by Tiger Trade Technology Pte. Ltd.

Clene Inc

3.86
-0.0200-0.52%
Post-market: 3.83-0.0276-0.72%19:59 EDT
Volume:48.11K
Turnover:186.08K
Market Cap:54.87M
PE:-1.10
High:3.96
Open:3.83
Low:3.80
Close:3.88
52wk High:13.50
52wk Low:3.25
Shares:14.21M
Float Shares:10.73M
Volume Ratio:0.47
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5038
EPS(LYR):-2.6548
ROE:-1738.36%
ROA:-56.88%
PB:-2.21
PE(LYR):-1.45

Loading ...

BRIEF-Clene Inc - Announces Common Stock Offering - SEC Filing

Reuters
·
May 06

Analysts Offer Insights on Consumer Goods Companies: Grupo Bimbo SAB de CV (OtherGRBMF), Clene (CLNN) and Fomento Economico Mexicano (FMX)

TIPRANKS
·
May 06

Analysts Are Bullish on Top Consumer Goods Stocks: BRC (BRCC), Clene (CLNN)

TIPRANKS
·
May 05

Clene (CLNN) Gets a Buy from JonesTrading

TIPRANKS
·
May 05

BRIEF-Clene Announces $7 Million Underwritten Offering Of Common Stock

Reuters
·
May 05

Clene prices 1,000,000-share registered direct offering at $7 per share

Reuters
·
May 05

Clene Inc - Prices 1,000,000 Share Underwritten Offering at $7.00 per Share

THOMSON REUTERS
·
May 05

Clene to present at Emerging Growth Conference virtual investor session

Reuters
·
May 05

Clene Price Target Maintained With a $31.00/Share by HC Wainwright & Co.

Dow Jones
·
May 05

Analysts Offer Insights on Consumer Goods Companies: Clene (CLNN) and Colgate-Palmolive (CL)

TIPRANKS
·
May 04

Clene Is Maintained at Buy by D. Boral Capital

Dow Jones
·
May 04

Clene provides update on NDA for ALS following Type C meeting with FDA

TIPRANKS
·
May 04

Clene says FDA open to accelerated approval review for CNM-Au8 ALS NDA

Reuters
·
May 04

BRIEF-After Successful FDA Meeting, Clene Filing Accelerated Approval NDA For Als

Reuters
·
May 04

After Successful FDA Meeting, Clene Filing Accelerated Approval Nda for ALS

THOMSON REUTERS
·
May 04

Clene Inc - FDA Acknowledges Nfl as Potential Surrogate Endpoint for Accelerated Approval

THOMSON REUTERS
·
May 04

Clene Inc - FDA Says Cnm-AU8 Data May Support Nda Under Accelerated Approval Pathway

THOMSON REUTERS
·
May 04

Clene Inc - Nda Submission Supported by Phase 2 Healey ALS and Rescue-ALS Trial Data

THOMSON REUTERS
·
May 04

Clene Inc - to Submit Nda for Cnm-AU8 to FDA in Q3 2026

THOMSON REUTERS
·
May 04

Clene Inc expected to post a loss of 62 cents a share - Earnings Preview

Reuters
·
May 01